Sanofi will discuss third-quarter 2026 results in an Oct. 30 webcast, following second-quarter sales growth of 17.8% at constant exchange rates (CER).
The company’s investor calendar schedules the webcast for 8:30 a.m. EDT (12:30 UTC) Friday. The one-hour session is set to end at 9:30 a.m. EDT (13:30 UTC). The event is listed as a review of Sanofi’s third-quarter results.
Sanofi reported second-quarter sales of €11.597 billion in results released July 30. Sales increased 17.8% at CER and 16% at actual exchange rates. The distinction matters when describing the growth: the 17.8% figure is on a constant-currency basis, while the actual-rate increase was lower.
Business earnings per share (EPS) was €2.09. Sanofi reported that it rose 33.3% at CER and 31.4% at actual exchange rates. The company attributed sales growth mainly to Pharma launches, including recent acquisitions, and Dupixent. It said disciplined cost management and one-off items supported EPS.
In its July outlook, Sanofi forecast full-year 2026 sales growth of about 10% at CER. It expected business EPS to grow slightly faster than sales, also at CER. Both parts of the outlook therefore use the constant-exchange-rate basis.
Sanofi’s investor calendar lists its Q4 and full-year 2026 results for Jan. 28, 2027.
